An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With low-and Int-1-risk Myelodysplastic Syndrome.
The primary purpose of this trial is to assess the effect of treatment with deferasirox
combined with erythropoietin vs. erythropoietin alone on erythropoiesis in patients with
low- and int-1-risk myelodysplastic syndrome.
The addition of deferasirox to erythropoietin could lead to a potential synergism with the
reduction of reactive oxygen species, through both the NF-kB pathway and the control of free
toxic iron. This may create a better environment in the bone marrow for a better response
This study is designed to test in a prospective way the combination of deferasirox with
erythropoietin in term of their effect on hematopoiesis.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society